Inhibikase Therapeutics raises $50M via ATM sale to RA Capital, extending cash runway through Phase 3 IMPROVE-PAH topline data readout.
Inhibikase Therapeutics (IKT) announced on Tuesday that it has sold 25M shares of its common stock to RA Capital Management through its at-the-market, or ATM, facility for gross proceeds of $50M. Shares of IKT dropped over 9% during pre-market trading hours. The company expects that the additional capital raised through this financing, together with existing cash reserves, will support operations through topline data readout in Part B of its ongoing global Phase 3 IMPROVE-PAH clinical study.
Source and reference
Source: press release
Read original source- Published
- Jul 14, 2026
- Updated
- Jul 14, 2026
- Source
- Seeking Alpha
- Category
- Health
- Read time
- 1 min
Key facts
Why this matters locally
This health story matters locally because it may affect readers, businesses, commuters, families, or public services in British Columbia.
Local impact
BC Post links this item to British Columbia coverage so readers can follow related city updates, weather, traffic, events, and category news in one place.
Timeline
Source and credit
BC Post may summarize, organize, and add local context for reader clarity. Original reporting remains with the listed publisher.
Related Articles
View all
Health
Provation Expands Global Footprint with Launch of Provation® Apex in Australia and New Zealand
Health
Neuroscientists find a teamwork paradox: highly synchronized brains perform worse at complex tasks
Health
The Surprising Cellular Benefit of the Pigment Behind Red Hair
Health
Andlauer-backed group loses bid for Château Montebello
Health
Coffee May Protect the Liver in More Ways Than Scientists Realized
More Local Coverage
Latest news
Business
AI Market Trends: Q2 2026 Review and Forecast
Politics
Powerful pro-life ad featuring boxing legend to air during final World Cup matches